BLAINJECTIONINJECTABLEPriority Review
Approved
Feb 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
ZEVALIN (ibritumomab tiuxetan) by Spectrum Dynamics is cd20 antigen (human b-lymphocyte-restricted differentiation antigen, bp35). Approved for refractory, low-grade, follicular b-cell non-hodgkin's lymphoma (nhl) () and 3 more indications. First approved in 2002.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEVALIN is a radiolabeled monoclonal antibody that targets CD20 antigen on B-cell lymphomas, combining ibritumomab (anti-CD20 mAb) with yttrium-90 radioisotope for targeted cytotoxicity. It treats refractory and low-grade follicular B-cell non-Hodgkin's lymphoma (NHL), including previously untreated disease and patients who achieved complete response to first-line chemotherapy. The drug induces cell death through free radical formation from Y-90 beta emission in target and neighboring malignant cells.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting contracting brand team and focus on retention rather than growth initiatives.
Mechanism of Action
CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35). The apparent affinity (K D ) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to 18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkin’s…
Indications (6)
Worked on ZEVALIN at Spectrum Dynamics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.